Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Attenuated Dengue-4 Virus Vaccine

---
identifier: "/us/fr/00-21793"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Attenuated Dengue-4 Virus Vaccine"
title_number: 0
title_name: "Federal Register"
section_number: "00-21793"
section_name: "Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Attenuated Dengue-4 Virus Vaccine"
positive_law: false
currency: "2000-08-25"
last_updated: "2000-08-25"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Defense Department"
document_number: "00-21793"
document_type: "notice"
publication_date: "2000-08-25"
agencies:
  - "Defense Department"
  - "Army Department"
fr_citation: "65 FR 51814"
fr_volume: 65
fr_action: "Notice."
---


#  Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Attenuated Dengue-4 Virus Vaccine

**AGENCY:**

U.S. Army Medical Research and Materiel Command, DoD.

**ACTION:**

Notice.

**SUMMARY:**

In accordance with 37 CFR 404.6, announcement is made of the availability for licensing of U.S. Patent Application Serial Number 09/534,726 entitled “Attenuated Dengue-4 Virus Vaccine”, filed March 24, 2000. Foreign rights are also available. This patent application has been assigned to the United States Government as represented by the Secretary of the Army.

**ADDRESSES:**

Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, Maryland 21702-5012.

**FOR FURTHER INFORMATION CONTACT:**

For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664. Both at telefax (301) 619-5034.

**SUPPLEMENTARY INFORMATION:**

The invention provides vaccine compositions of attenuated dengue-4 virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against dengue-4 virus by administration of attenuated dengue-4 virus.

Gregory D. Showalter,

Army Federal Register Liaison Officer.